Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moonlight-1: JNJ-89495120 in Major Depressive Disorder
NCT06785012Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PIPE-307 in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Dec 2024; status: completed.
02
Drugs
PIPE-307
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06785012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06785012.